• 25-Hydroxycholesterol Reprograms Macrophages via Lysosomal A

  2026-06-27

  Xiao et al. (2024) reveal how 25-hydroxycholesterol (25HC), produced by CH25H, accumulates in lysosomes of tumor-associated macrophages to activate the AMPKa pathway and drive immunosuppression. This mechanistic insight links cholesterol metabolism to immune cell fate and suggests new immunometabolic checkpoints and therapeutic strategies for cancer.

• ZNF706 as a Diagnostic and Therapeutic Target in Hepatocellu

  2026-06-26

  The referenced study identifies Zinc Finger Protein 706 (ZNF706) as a highly promising biomarker and potential therapeutic target in hepatocellular carcinoma (HCC). Through integrative bioinformatic analysis and functional experiments, ZNF706 was found to be overexpressed in HCC, correlating with advanced disease and poor prognosis—highlighting its value for future diagnostic assay development.

• Telmisartan in Cardiac Hypertrophy Research: Protocols & Adv

  2026-06-26

  Telmisartan, a potent angiotensin II receptor antagonist from APExBIO, is reshaping cardiac hypertrophy research by enabling targeted modulation of critical signaling pathways. This article delivers actionable workflows, troubleshooting strategies, and practical guidance for leveraging Telmisartan in experimental cardiovascular models.

• Patient-Derived Gastric Cancer Assembloids Reveal Stromal Im

  2026-06-25

  This study presents a novel gastric cancer assembloid model integrating matched tumor organoids and patient-specific stromal cell subpopulations, enabling more physiologically relevant preclinical drug testing. By capturing the complexity of tumor–stroma interactions, the model offers improved insights into drug resistance and supports the development of personalized therapies.

• Tubastatin A: HDAC6 Inhibition for Microtubule Stability and

  2026-06-25

  Explore how Tubastatin A, a potent HDAC6 inhibitor, uniquely stabilizes microtubules and mitigates cardiac injury by modulating cell death pathways. This in-depth review connects molecular mechanisms to translational research, offering fresh insights for disease modeling.

• GDC-0941: PI3K Inhibitor Workflows for Cancer Research Excel

  2026-06-24

  GDC-0941 offers reproducible, high-impact PI3K/Akt pathway inhibition for cancer cell proliferation and resistance models, including trastuzumab-resistant HER2-amplified lines. Unlock advanced workflows, troubleshooting strategies, and comparative advantages for translational oncology with this validated APExBIO tool.

• Precision Apoptosis Detection: Driving Translational Innovat

  2026-06-23

  This article explores the mechanistic and translational imperatives of apoptosis detection in the era of cancer therapy resistance. We dissect the biological underpinnings of DNA fragmentation, contextualize recent advances in TKI resistance mechanisms, and provide actionable guidance on deploying the One-step TUNEL Cy5 Apoptosis Detection Kit for robust research outputs. By integrating novel insights from the latest literature and benchmarking against field standards, we empower translational researchers to elevate experimental rigor and clinical relevance.

• HyperScribe All in One mRNA Synthesis Kit Plus 1: Applied Wo

  2026-06-23

  The HyperScribe All in One mRNA Synthesis Kit Plus 1 delivers rapid, high-yield ARCA-capped mRNA with immune-evasive modifications, streamlining the workflow for in vitro translation, RNA vaccine development, and RNAi experiments. Its integrated poly(A) tailing and optimized nucleotide modifications offer superior stability and translational efficiency, empowering researchers to achieve reliable experimental outcomes.

• Solving Lab Challenges with Annexin V-APC/7-AAD Apoptosis Ki

  2026-06-22

  This article explores how the Annexin V-APC/7-AAD Apoptosis Kit (SKU K2297) addresses persistent challenges in apoptosis and necrosis detection for biomedical researchers. Scenario-driven Q&A reveals evidence-based strategies for reproducibility, workflow efficiency, and data quality in cell death assays, highlighting the kit's practical impact on advanced research workflows.

• Perphenazine in Host-Directed Research: Beyond Dopamine Anta

  2026-06-22

  Explore how Perphenazine, a dopamine D2 receptor antagonist, transforms host-directed research by linking neuropharmacological mechanisms to innate immunity and antibacterial applications. Discover detailed protocols, innovative findings, and critical assay insights for schizophrenia and infection studies.

• Cefodizime: Third-Generation Cephalosporin for Robust Antiba

  2026-06-21

  Cefodizime, a third-generation cephalosporin antibiotic from APExBIO, empowers infectious disease researchers with broad-spectrum activity and unique immunomodulatory properties. Its β-lactamase stability and reliable kidney-safe profile streamline experimental workflows for both Gram-positive and Gram-negative infection models.

• Saquinavir and the Future of HIV Protease Inhibitor Research

  2026-06-20

  This thought-leadership article explores the mechanistic basis, translational impact, and emerging validation strategies for Saquinavir, a benchmark HIV protease inhibitor. It uniquely bridges cutting-edge permeability modeling with practical guidance for antiretroviral and cancer researchers, integrating fresh evidence from biomimetic chromatography studies and offering actionable protocol parameters. Compared to conventional product pages, this piece provides in-depth strategic perspective for translational workflows and highlights new frontiers in experimental pharmacology.

• PBS (Phosphate-Buffered Saline): Technical Guide and Protoco

  2026-06-19

  PBS (Phosphate-Buffered Saline, SKU K2818) provides a sterile, isotonic buffer solution that reliably maintains physiological pH and osmolarity, supporting reproducible cell washing and dilution steps in laboratory workflows. It should be used exclusively for in vitro research and is not appropriate for diagnostic or clinical applications.

• β-Elemene: Advanced Mechanistic Insights and Translational P

  2026-06-19

  Explore β-Elemene’s (Levo-β-elemene) unique mechanistic actions and translational utility in metabolic and neural research models. This article delivers a deep-dive into protocol parameters and practical assay decisions for β-Elemene, distinguishing itself from existing literature.

• CP-673451: Selective PDGFRα/β Inhibitor for Cancer Research

  2026-06-18

  CP-673451 enables rigorous dissection of PDGFR-driven angiogenesis and tumor growth with unmatched selectivity, making it a linchpin for translational cancer research. Its performance in ATRX-deficient glioblastoma models sets a new benchmark for targeted assay design and precision troubleshooting.

448 records 13/30 page Previous Next First page 上5页 1112131415 下5页 Last page